News | December 15, 2010

aycan, Definiens Partner to Market Lung Tumor Detection Solution


December 15, 2010 – Definiens and aycan have formed a partnership to complete the first joint project to quantify and analyze lung tumors.

Under the partnership, Definiens has combined its LungExpert with aycan’s OsiriX PRO to create a workstation that quantifies lung tumors according to RECIST and WHO guidelines and also by their volume. This new integrated solution enables efficient analysis of lesions, including automated quantification of lung tumors.

The new workstation is expected to be available in early 2011.

For more information: www.aycan.com, www.definiens.com

Related Content

NANO-X ARC
News | Computed Tomography (CT)
Nanox Gets FDA Clearance for New Imaging System

April 17, 2025 — Nano-X Imaging LTD has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for ...

Time April 18, 2025
arrow
Konic Minolta Exa PACS
News | PACS
Konica Minolta Launches Next-Gen Exa Platform with Embedded Advanced Visualization Functionality

April 3, 2025 – Konica Minolta Healthcare Americas, Inc. has launched the next-generation of the Exa Platform with the ...

Time April 15, 2025
arrow
News | Enterprise Imaging
Konica Minolta Healthcare Debuts Exa Enterprise

Nov. 13, 2024 – Konica Minolta Healthcare Americas, Inc.has launched Exa Enterprise, an enterprise imaging solution with ...

Time November 14, 2024
arrow
News | Artificial Intelligence
eBook on AI's Role in Lung Cancer Diagnosis Now Available

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class III medical device license from Health Canada for all its medical imaging AI solutions according to a statement released by the company, led by co-founder and CEO, Prashant Warier.
News | Artificial Intelligence
Qure.ai Receives Class III Medical Device License Approval from Health Canada 

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
MD Anderson researchers demonstrate value of IMRT compared to 3D-CRT, validate heart exposure as important radiation planning objective
News | Radiation Therapy
Study Supports Precision Radiation Therapy in Lung Cancer

July 3, 2024 — Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support ...

Time July 03, 2024
arrow
Thirona, a provider of advanced lung image analysis with artificial intelligence, led by scientist now CEO Eva van Rikxoort, has recently announced multiple partnerships.
News | Artificial Intelligence
Thirona Announces Partnerships to Enhance AI-based Lung Image Analysis

June 27, 2024 — Thirona, a Netherlands-based global company providing high-precision advanced lung image analysis with ...

Time June 27, 2024
arrow
A new study led by researchers at Emory AI.Health, published in the Journal of Computers in Medicine and Biology, sheds light on the significant lung damage caused by severe COVID-19.
News | Artificial Intelligence
Study Applying AI to CT Scans Unveils Lung Damage Severity in COVID-19 Patients

June 11, 2024 — A new study led by researchers at Emory AI.Health, published in the Journal of Computers in Medicine and ...

Time June 11, 2024
arrow
Medtronic has reported preliminary findings of the first and only head-to-head trial comparing standard-of-care CT-guided biopsy with electromagnetic navigation bronchoscopy (ENB) for the diagnosis of lung nodules.
News | Radiology Business
Medtronic Announces Positive Preliminary Data from VERITAS Clinical Study at American Thoracic Society, ATS 2024

May 22, 2024 — Medtronic has announced new preliminary data from the VERITAS clinical study using its ILLUMISITE ...

Time May 22, 2024
arrow
Brandon Suh, CEO of Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and therapeutics, today announced the successful completion of its acquisition of Volpara Health Technologies, a global developer of medical software for breast cancer screening.
News | Artificial Intelligence
Lunit Announces Completion of Volpara Acquisition to Advance AI-driven Cancer Care

May 22, 2024 — Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and ...

Time May 22, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now